Oxford BioMedica plc  

(Public, LON:OXB)   Watch this stock  
Find more results for OXB
-0.04 (-1.54%)
Real-time:   11:46AM GMT+1
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 2.87 - 2.88
52 week 1.38 - 3.80
Open 2.92
Vol / Avg. 113,682.00/2.40M
Mkt cap 71.84M*
P/E     -
Div/yield     -
EPS -0.01*
Shares 2.49B
Beta     -
Inst. own     -
Aug 28, 2014
Interim 2014 Oxford BioMedica PLC Earnings Release (Estimated) Add to calendar
Jun 23, 2014
Oxford BioMedica plc at Piper Jaffray Gene Therapy Conference
Jun 23, 2014
Oxford BioMedica plc at Biotechnology Industry Organization (BIO) International Convention
Jun 16, 2014
Oxford BioMedica PLC General Meeting
Jun 3, 2014
Oxford BioMedica PLC Annual General Meeting
May 29, 2014
Oxford BioMedica PLC Fundraising and Open Offer Conference Call
May 13, 2014
Oxford BioMedica PLC Interim Management Statement for the period 1 January to 12 May 2014

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -160.45% -206.44%
Operating margin -186.46% -238.57%
EBITD margin - -218.72%
Return on average assets -65.18% -58.30%
Return on average equity -91.17% -77.75%
Employees 95 -
CDP Score - -


Medawar Centre Robert Robinson Avenue The Oxford Science Park
Oxford, ENG OX4 4GA
United Kingdom - Map
+44-1865-783000 (Phone)
+44-1865-783001 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Oxford BioMedica plc (Oxford BioMedica) is a biopharmaceutical company developing gene-based medicines and therapeutic vaccines. The Company is evaluating product candidates for four ocular indications, including uveitis and three undisclosed genetic retinal diseases. The Company's technology platform includes a LentiVector gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a tumour antigen (5T4), which is a target for anti-cancer therapy. Its partnership with Sanofi comprises four LentiVector platform product candidates for four ocular indications: RetinoStat for wet age-related macular degeneration (AMD), StarGen for Stargardt disease, UshStat for Usher syndrome type 1B, and EncorStat for corneal graft rejection. Its manufacturing capabilities cover the entire product lifecycle; from pre-clinical development, to regulatory support, to all future stages of viral vector product clinical development.

Officers and directors

John Dawson Chief Executive Officer, Executive Director
Age: 54
Tim Watts Chief Financial Officer, Company Secretary, Executive Director
Age: 55
Peter Nolan Senior Vice President - Commercial Development, Executive Director
Age: 60
Nicholas Rodgers Non-Executive Independent Chairman of the Board
Andrew J. Heath M.D., Ph.D. Non-Executive Deputy Chairman of the Board, Senior Independent Director
Age: 64
Martin Diggle Non-Executive Director
Age: 50
Paul Blake M.D. Non-Executive Independent Director
Age: 65